Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy (HPV)

This study has been completed.
Sponsor:
Collaborators:
Harvard School of Public Health
Merck Sharp & Dohme Corp.
Information provided by:
Boston Children’s Hospital
ClinicalTrials.gov Identifier:
NCT00727636
First received: July 31, 2008
Last updated: May 3, 2011
Last verified: May 2011
Results First Received: May 3, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Inflammatory Bowel Disease
Intervention: Biological: Gardasil vaccine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Location - Children’s Hospital Boston, including Waltham Infusion Center, and Maine Medical Center. Patients were recruited during a scheduled clinical or Remicade infusion visit, a hospital admission, by contact through mail followed by a phone call, or through referral from local hospitals. Recruitment period -April 2008 through April 2010

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Prospective Cohort Received Gardasil as part of study
Retrospective Cohort Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine

Participant Flow:   Overall Study
    Prospective Cohort   Retrospective Cohort
STARTED   37   15 
COMPLETED   33   15 
NOT COMPLETED   4   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Prospective Cohort Received Gardasil as part of study
Retrospective Cohort Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine
Total Total of all reporting groups

Baseline Measures
   Prospective Cohort   Retrospective Cohort   Total 
Overall Participants Analyzed 
[Units: Participants]
 37   15   52 
Age 
[Units: Participants]
     
<=18 years   33   6   39 
Between 18 and 65 years   4   9   13 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 14.9  (3.1)   18.9  (3.5)   16.1  (3.6) 
Gender 
[Units: Participants]
     
Female   37   15   52 
Male   0   0   0 
Region of Enrollment 
[Units: Participants]
     
United States   37   15   52 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Antibody Titer to HPV 6   [ Time Frame: Month 7 ]
  Hide Outcome Measure 1

Measure Type Primary
Measure Title Antibody Titer to HPV 6
Measure Description No text entered.
Time Frame Month 7  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Prospective Cohort Received Gardasil as part of study
Retrospective Cohort Patients received Gardasil vaccine from their primary medical provider. They had blood drawn for the study after they completed the vaccine

Measured Values
   Prospective Cohort   Retrospective Cohort 
Participants Analyzed 
[Units: Participants]
 33   15 
Antibody Titer to HPV 6 
[Units: milli-Merck units/mL]
Geometric Mean (95% Confidence Interval)
 1079.9 
 (783 to 1489.3) 
 173.4 
 (91.3 to 329.5) 

No statistical analysis provided for Antibody Titer to HPV 6



2.  Primary:   Antibody Titer to HPV 11   [ Time Frame: Month 7 ]

3.  Primary:   Antibody Titers to HPV 16   [ Time Frame: Month 7 ]

4.  Primary:   Antibody Titer to HPV 18   [ Time Frame: Month 7 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information